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1. Introduction 
Mesenteric ischaemia due to impaired arterial supply is an important cause of abdominal 
pain, especially in older patients with risk factors for vascular disease. Until recently, 
surgical revascularisation procedures such as endarterectomy and aorto-coeliac or aorto-
mesenteric bypass grafting were the only available treatment options for patients with 
mesenteric ischaemia. However, reported rates of peri-operative major complications and 
mortality are high, influenced by a high prevalence of significant patient co-morbidities. 
Percutaneous angioplasty and stenting have been shown to be effective and safe alternatives 
to surgical revascularisation in high-risk patients with mesenteric ischaemia. Indeed, in 
high-surgical risk patients and in those with suitable lesions, such endovascular 
revascularisation has emerged as the primary treatment modality.  
Here, we review current concepts in the diagnosis, treatment selection and outcomes for 
percutaneous angioplasty and stenting for patients with either chronic or acute mesenteric 
ischemia. 
2. Chronic mesenteric ischaemia 
Chronic mesenteric ischaemia (CMI) most commonly arises from atherosclerotic diseases of 
the mesenteric arteries. Other causes of CMI include aortic dissection, fibromuscular 
dysplasia, vasculitides and median arcuate ligament syndrome.  
Atherosclerotic disease of the mesenteric arteries is estimated to occur in 17% of patients 
over the age 65 years (Hansen et al., 2004). Despite its prevalence, the majority of these 
patients are asymptomatic as a result of the extensive collateral circulation between the 
celiac trunk, superior mesenteric artery (SMA) and inferior mesenteric artery (IMA). 
Whether or not ischaemia ensues depends on the site of the stenosis or occlusion and the 
development or otherwise of collateral vessels (Loffroy et al., 2009). CMI typically occurs in 
patients who have SMA lesions in conjunction with lesions in either the celiac trunk or IMA. 
However, mesenteric ischaemia can also develop in patients with a single vessel lesion. 
Distal lesions are more likely to be symptomatic compared with more proximal arterial 
pathology due to the absence of an effective collateral circulation.  
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3. Clinical presentation 
CMI commonly affects people over the age of 60 years, with women three times more likely 
to be affected than men (Hansen et al., 2004). Most patients have multiple cardiovascular 
risk factors and atherosclerotic complications in other vascular territories.  
Classic symptoms of CMI include postprandial abdominal pain, fear of eating and 
significant weight loss. Patients may also present with persistent nausea and diarrhoea. 
These symptoms are non-specific and extensive investigations are generally undertaken to 
exclude other pathologies such as gastrointestinal or pancreatic malignancy.  
4. Diagnosis  
Duplex ultrasound is a useful, non-invasive screening test for mesenteric ischaemia (Moneta 
et al., 1993) (Table 1). Its accuracy is affected by operator experience and patient factors such 
as fasting status, body habitus and presence of bowel gas. CT-angiography and MR-
angiography are of value in cases where duplex ultrasound is inconclusive (Cademartiri et 
al., 2008; Horton et al., 2007; Laissy et al., 2002). CT-angiography also provides excellent 3-D 
anatomical reconstruction to facilitate planning for endovascular revascularisation. 
Nevertheless, digital subtraction angiography remains the gold standard in evaluating the 
degree of stenosis in mesenteric vessels.  
 
Vessel Duplex criteria Sensitivity Specificity Accuracy 
SMA PSV > 275cm/s 92% 96% 96% 
Coeliac trunk PSV > 200cm/s 87% 82% 82% 
PSV: peak systolic velocity 
Table 1. Duplex ultrasound criteria for detecting >70% stenosis in mesenteric vessels (from 
Moneta et al., 1993).  
5. Treatment options 
Treatment of symptomatic CMI is aimed at relieving symptoms and preventing progression to 
acute mesenteric ischaemia (AMI) and intestinal infarction. Prophylactic treatment of 
asymptomatic patients is controversial. The risk of progressing to AMI is greatest in patients 
with three-vessel disease with an estimated one third of these patients progressing to intestinal 
infarction if left untreated (Kolkman et al., 2004). The prognosis is relatively benign in those 
with single-vessel disease. In participants of the Cardiovascular Health Study who were found 
to have isolated coeliac trunk or mesenteric artery disease on duplex ultrasound, there was no 
increased risk of mortality, intestinal infarction or development of symptoms consistent with 
CMI over a median follow up period of 6.5years (Wilson et al., 2006).  
The gold standard of treatment has traditionally been surgical revascularisation in the form 
of bypass, endarterectomy or embolectomy. Given that patients affected by CMI are 
generally malnourished, of advanced age and have multiple cardiovascular co-morbidities, 
there is considerable peri-operative mortality (0-17%) and morbidity (15-33%) associated 
with surgical revascularisation (Kougias et al., 2009).  
Endovascular revascularisation is increasingly being offered to patients affected by CMI. In 
a large US registry study comprising of 5583 patients treated for CMI during the years 1988 
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to 2006 (Schermerhorn et al., 2009), the number of endovascular procedures steadily 
increased, surpassing all surgery for CMI in 2002. Endovascular revascularisation is 
associated with a lower in-hospital mortality and morbidity rate as well as shorter length of 
stay. Significantly lower rates of bowel resection, as well as fewer renal, cardiac and 
respiratory complications have been reported in patients who received endovascular 
revascularisation compared to surgically-treated counterparts (Table 2). A later analysis of 
published data concerning procedures performed between 2000 and 2009 similarly 
demonstrated a significantly reduced peri-operative complication rate in patients managed 
by endovascular therapy compared to surgery (Gupta et al., 2010). 
 
 Endovascular 
revascularisation 
Surgical 
revascularisation 
p-
value 
Mortality 3.7% 15.4% <0.001 
Overall morbidity 20% 38% <0.05 
Bowel resection 3% 8% <0.001 
Cardiac events 0.7% 5.9% <0.001 
Respiratory events 0.3% 5.7% <0.001 
Acute renal failure 6.0% 10.5% <0.05 
LOS                               
median (range), days 
5 (0-94) 11 (1-135) <0.001 
Table 2. Mortality, morbidity, peri-operative complications and length of stay (LOS): 
endovascular revascularisation vs. surgical revascularisation. (adapted from Schermerhorn 
et al., 2009)  
A serious potential complication of endovascular treatment is the precipitation of acute 
intestinal ischemia by plaque embolization or dissection of the artery. Standard catheter 
based salvage techniques such as stent deployment, embolectomy or thrombolysis are 
usually successful in treating these complications. Emergency laparotomy with mesenteric 
bypass and bowel resection is also used as salvage treatment. We recently reported the 
occurrence of splenic infarction complicating otherwise successful celiac artery stenting, 
presumably as a consequence of distal embolization of disrupted calcific plaque, with this 
complication representing a novel cause of abdominal pain post-procedure (Almeida & 
Riordan, 2008). 
The most common procedural complication of endovascular therapy relates to the puncture 
site, manifesting as either haemorrhage or thrombosis. Haemorrhage is generally controlled 
with local pressure and/or injection of thrombin. Insertion of interventional sheaths in small 
arteries is associated with an increased risk of thrombosis. Rapid heparinization after sheath 
insertion is usually an adequate preventative measure. 
Another important issue is the longer-term arterial patency rate in patients treated by 
endovascular means compared to those managed surgically. In a recent review of 328 
patients undergoing endovascular treatment for chronic mesenteric ischaemia, the overall 
technical success rate was 91% and immediate symptomatic relief was achieved in 82% of 
patients (Kougias et al., 2007). Despite the initial success rate, approximately one third of 
patients (84/292) available for follow up developed restenosis over a mean follow up period 
of 26 months. The 30-day mortality rate was 3-5%. Clinical series comparing endovascular 
and surgical revascularisation have shown that long term patency rates and freedom from 
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symptoms may be inferior in patients who have had endovascular revascularisation 
(Kougias et al., 2009; Atkins et al., 2007; Kasiragjan et al., 2001). Indeed, an analysis of all 
published literature comparing surgical and endovascular treatment options for CMI 
performed between 2000 and 2009 concluded that 5-year primary patency rates were 3.8 
times greater in the surgical group (P<0.001), while freedom from symptoms at 5 years was 
4.4 times greater in patients managed surgically compared to those treated with 
endovascular techniques (p<0.001) (Gupta et al., 2010). 
6. Angioplasty vs stenting 
There is general agreement that stenting is indicated for residual stenosis following primary 
angioplasty (defined as residual stenosis of 30% or more, or pressure gradient higher than 
15mmHg), for ostial or eccentric lesions, or as a salvage procedure for acute dissection after 
angioplasty (Kougias et al., 2007).  Balloon-expandable stents are preferred because of their 
accuracy and ability to generate considerable radial force. More distal or long lesions may be 
better suited to self-expandable stents given their flexibility (Loffroy et al., 2009).  
Kougias et al (2007) reported that technical success was significantly higher with stenting 
compared with angioplasty alone (95% vs 83%, p=0.007), although the rate of restenosis was 
also higher in the stented subgroup, a finding that may have been biased by the inclusion of 
earlier studies where more primitive stents were used and peri-procedural anticoagulant 
and antiplatelet treatment regimens were not standardized. A recent case series 
demonstrated that long-term patency rate was higher in patients managed with primary 
stenting compared to angioplasty alone (Daliri et al., 2010). 
7. Which vessel to treat 
Literature from the surgical revascularisation setting has shown that complete 
revascularisation of the coeliac trunk and SMA is associated with improved long-term 
outcomes (Mateo et al., 1999; McAfee et al., 1992; Foley et al., 2000). The simultaneous 
treatment of two vessels prevents symptom recurrence in the event of restenosis in either 
artery. Improved graft patency and survival with complete reconstruction (McAfee et al., 
1992), and a higher incidence of symptoms and graft failure with single vessel therapy 
(Foley et al., 2000) have each been demonstrated.  
There is a tendency to treat fewer vessels when choosing endovascular revascularisation 
compared with surgical revascularisation (Kougias et al., 2009). The conventional approach 
to endovascular intervention is to treat SMA lesions in preference to celiac trunk or IMA 
lesions. There is conflicting evidence as to whether treatment of both SMA and celiac 
arteries will produce better long-term patency. A recent series by Peck et al indicated that 
two-vessel treatment resulted in lower symptomatic recurrences, improved patency and 
fewer re-interventions (Peck et al., 2010). On the other hand, Sarac et al. (2008) did not report 
any difference in 1 year patency between single-vessel and two-vessel treatment, while 
Malgor et al. (2010) similarly found in a study of longer follow-up of 3 years that two-vessel 
celiac  artery and SMA stenting did not result in improved outcomes when compared with 
single-vessel SMA stent placement for CMI. 
Traditionally, there has been a preference for treating stenotic rather than occlusive lesions 
by endovascular means. Although the presence of an occluded vessel is not an absolute 
contraindication to endovascular intervention, the practice in many centres is to convert 
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from endovascular to open surgical revascularisation when an occlusion is found 
(Kasiragjan et al., 2001).  Endovascular passage of guide wires and stents through totally 
occluded lesions is a technically challenging procedure and not without significant risks of 
vessel perforation or dissection. Although not statistically validated, the degree of difficulty 
is likely to increase with the length of occlusion. A theoretical concern also exists for plaque 
fragmentation and distal embolization, which also increases with the length of occlusion.   
Although the efficacy of endovascular intervention in treating occluded mesenteric vessels 
is not well established, evolving endovascular technology with low-profile systems has now 
made recanalization of occluded vessels feasible. Landis et al. (2005) reported technical 
success and 1-year patency rates of 100% in 9 patients with mesenteric occlusion. A case 
series by Peck et al also indicated that patients with occluded SMA who underwent 
revascularisation had lower 3-year symptom recurrence rates, with three year patency rates 
of 90% for treated SMA occlusions versus 40% for untreated SMA occlusions (Peck et al., 
2010). This difference however was not statistically significant, possibly due to the small 
numbers of patients studied.  
8. Surveillance of vessel patency 
There is a lack of uniformity in the follow up of patients who have received endovascular 
therapy for CMI. Although recurrence of symptoms is correlated with restenosis, this alone 
is not a reliable predictor of vessel patency, with sensitivity as low as 33% for detection of 
restenosis (McMillan et al., 1995). Failure to diagnose progressive disease in asymptomatic 
patients may result in the subsequent development of acute mesenteric thrombosis. This is a 
potentially fatal vascular emergency with overall mortality rate ranging from 32% to 65% 
(Park et al., 2002).  
Abdominal duplex ultrasonography is the most commonly used method of surveillance due 
to its non-invasive nature. Although duplex ultrasonography has been validated in the 
diagnosis of mesenteric arterial stenosis (Zwolak et al., 1998), there is no current consensus 
on which velocity criteria should be used to define high-grade recurrent disease (Kasirajan 
et al., 2001; Armstrong et al., 2007; Fenwick et al., 2007). CT-angiography and MR-
angiography are alternative modalities of imaging, although digital substraction 
angiography is generally considered the gold standard. There is a potential role for 
functional studies such as gastrointestinal tonometry to detect mesenteric ischemia and 
guide treatment (Otte et al., 2008).   
9. Acute mesenteric ischemia 
Acute mesenteric ischemia is associated with a daunting mortality rate of greater than 50% 
(Schermerhorn et al., 2009). Prompt diagnosis and institution of revascularisation therapy 
are crucial for a successful outcome.  
Endovascular treatment for AMI was traditionally reserved for selected patients who have 
prohibitive operative risk, no clinical signs of peritoneal inflammation, or those with a 
contaminated peritoneal cavity and no autogenous vessel available for grafting (Loffroy et 
al., 2009). With evolving expertise and technological advancements in endovascular therapy, 
there has been an increase in the use of endovascular revascularisation for treatment of AMI. 
In the US registry study of 5237 patients treated for AMI, the outcomes of patients who were 
treated with endovascular intervention were compared to those who were treated with 
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surgery (Schermerhorn et al., 2009). Patients who were treated with endovascular measures 
tended to have higher rates of cardiovascular comorbidities than those undergoing open 
surgical repair, including hypertension, peripheral vascular disease, coronary artery disease 
and chronic renal failure. Despite these unfavourable patient characteristics, mortality was 
significantly lower in the endovascular group compared with the surgical group (16% vs 
39%, p<0.001).  
In a recent retrospective, single centre case series of 70 patients with AMI, the largest such 
case series to date, Arthurs et al. (2011) demonstrated that the use of endovascular therapy 
as primary treatment for AMI produced lower complication rates and better outcomes 
(Arthurs et al., 2011). During a 9-year study period, endovascular therapy was initiated in 56 
patients while surgical therapy was used in 24 patients. Overall, technical success for 
endovascular therapy was 87%. Failures in endovascular therapy were treated with 
embolectomy in 78% and revascularisation in 22%. Successful endovascular treatment 
resulted in a mortality rate of 36%, which was significantly lower compared with a rate of 
50% in those treated surgically (p<0.05). Patients who failed endovascular treatment had a 
mortality rate of 50%, an outcome which was equivalent to that of traditional surgical 
therapy. Block et al. (2010) have also recently reported improved 30 day and long-term 
survival with endovascular revascularisation of the SMA compared to surgery in patients 
identified through the Swedish Vascular Registry from 1999 to 2006, although the need for 
prospective randomised data to confirm group differences was highlighted. 
The general view that laparotomy is crucial for all patients with AMI to assess intestinal 
viability and perform resection as required has also recently been questioned. Arthurs et al. 
(2011) challenged this philosophy by performing laparotomy only on patients who had 
signs of peritoneal inflammation or deteriorated clinically following initial revascularisation. 
Over 30% of patients in the endovascular therapy group did not ultimately require 
laparotomy, thereby avoiding further physiologic insult to patients who are already 
critically ill.   
Another important issue is to what extent ischaemia-reperfusion injury of the intestine, 
leading to microvascular injury and cellular necrosis and apoptosis, contributes to morbidity 
and mortality in patients in whom arterial revascularisation is attained and whether various 
recent advances in preventing or limiting this phenomenon described in the experimental 
situation can be translated clinically (Santora et al., 2011; Petrat & de Groot, 2011; Flessas et 
al., 2011).  
10. Conclusions 
There has been a recent paradigm shift in the treatment of mesenteric ischaemia. Whereas 
endovascular therapy was once reserved for the few patients who had prohibitive operative 
risks, it is now increasingly used for revascularisation of both chronic and acute mesenteric 
ischemia. Endovascular therapy is less invasive than open surgery, and is associated with 
lower peri-procedural morbidity and mortality. There is growing evidence that stenting 
may achieve better technical success and patency rates compared with angioplasty alone. 
The timing and choice of imaging modality for surveillance of vessel patency remains an 
important question for clinicians. Effective approaches to improving longer-term vessel 
patency rates following endovascular therapy are required, along with strategies to prevent 
ischaemia-reperfusion injury in those patients with acute mesenteric ischaemia in whom 
revascularisation is achieved. 
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